Abstract
Abstract
Purpose
Chemotherapy (CTX) is an important part of the treatment strategy of stage II–IV ovarian cancer. CTX modifications, such as delays, dose reductions or premature terminations might have a negative impact on overall survival (OS) and progression free survival (PFS). The goal of this study was to determine the incidence and predictors of CTX modifications and their influence on survival.
Methods
An observational retrospective cohort analysis of 192 ovarian cancer patients who were treated at the Department of Obstetrics and Gynaecology, Technical University Munich, Germany, according to international guidelines was performed including from 2009 to 2013. A potential association between patient and disease characteristics and CTX modifications was tested with multivariate logistic regression. OS and PFS were estimated by Kaplan–Meier analysis.
Results
44.8% (86/192) received a modification of CTX. 34 (17.7%) women discontinued CTX prematurely, 17 (8.9%) underwent a dose reduction, 16 (8.3%) experienced a CTX delay and 10 (5.2%) had both a delay and a dose modification. In nine (4.7%) patients, the dose needed to be divided. Leukopenia (p < 0.001) and anaemia (p = 0.003) were significantly more common in patients with CTX modifications. Significant predictors for CTX modifications were a history of thrombosis or embolism (p < 0.001) and residual tumour postoperatively (p = 0.003).
Patients with CTX modifications showed a significantly lower OS as well as PFS (p < 0.001), even after adjustment for prognostic factors such as age, body-mass-index, residual tumour, histology, FIGO stage and grading (p = 0.005 for OS and p = 0.001 for PFS).
Conclusion
CTX modifications have a negative impact on survival. Significant predictors for such modifications are a history of thrombosis or embolism and the presence of residual postoperative tumour. Further studies are needed to avoid CTX modifications and to improve survival of ovarian cancer patients.
Funder
Technische Universität München
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology,General Medicine
Reference20 articles.
1. Reid BM, Permuth JB, Sellers TA (2017) Epidemiology of ovarian cancer a review. Cancer Biol Med 14:9–32
2. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner. Ovarialtumoren, Langversion 5.0, 2021, AWMF-Registernummer: 032/035OL, https://www.leitlinienprogramm-onkologie.de/leitlinien/ovarialkarzinom/
3. Heilmann T, Pfisterer J, Hempel AM, Saß S, Hedderich J, Pujade-Lauraine E et al (2019) Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years. Gynecol Oncol 153(3):616–624. https://doi.org/10.1016/j.ygyno.2019.02.015
4. Salman L, Ben-Haroush A, Raban O, Yeoshoua E, Sabah G, Jakobson-Setton A et al (2019) Neoadjuvant chemotherapy treatment modifications in ovarian carcinoma: the impact on surgical outcome and progression-free survival. Ame J Clin Oncol 42(1):17–20. https://doi.org/10.1097/COC.0000000000000469
5. Denduluri N, Lyman GH, Wang Y, Morrow PK, Barron R, Patt D et al (2018) Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian cancer. Clin Breast Cancer 18(5):380–386. https://doi.org/10.1016/j.clbc.2018.02.003
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献